A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: An Eastern Cooperative Oncology Group Trial

Breast Cancer Research and Treatment

Volumn 119, Issue 3, 2010, Pages 663-671

  Moulder, Stacy ^a   Li, Hailun ^b   Wang, Molin ^b   Gradishar, William J ^c   Perez, Edith A ^d   Sparano, Joseph A ^e   Pins, Michael ^c   Yang, Ximing ^c   Sledge, George W ^f  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d MAYO CLINIC   (United States)

^e MONTEFIORE MEDICAL CENTER   (United States)

^f INDIANA UNIVERSITY   (United States)

Author keywords

Breast cancer; Carboplatin; Trastuzumab; Weekly ixabepilone

Indexed keywords

ANTIEMETIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CARBOPLATIN; DIPHENHYDRAMINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IXABEPILONE; LOPERAMIDE; PACLITAXEL; RANITIDINE; TRASTUZUMAB;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BONE METASTASIS; BRAIN DISEASE; BRAIN METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED STUDY; COUGHING; DEHYDRATION; DESQUAMATION; DIARRHEA; DISTANT METASTASIS; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; EMBOLISM; FATIGUE; FEBRILE NEUTROPENIA; HEADACHE; HEART LEFT VENTRICLE FAILURE; HEMATOLOGIC DISEASE; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; INSOMNIA; LIMB PAIN; LIVER METASTASIS; LIVER TOXICITY; LOADING DRUG DOSE; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; MOTOR NEUROPATHY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA METASTASIS; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; SKIN INFECTION; SKIN METASTASIS; STOMATITIS; SYNCOPE; TASTE DISORDER; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; URINARY TRACT INFECTION; VOMITING; WEAKNESS; WEIGHT REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; EPOTHILONES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KAPLAN-MEIERS ESTIMATE; MIDDLE AGED; RECEPTOR, ERBB-2;

EID: 74849122823     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0658-9     Document Type: Article

References (29)

1. DJ Slamon B Leyland-Jones S Shak, et al. 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 783 792 10.1056/NEJM200103153441101 1:CAS:528: DC%2BD3MXisVGktrc%3D 11248153 (Pubitemid 32222155)
2. H Burris III D Yardley S Jones, et al. 2004 Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer J Clin Oncol 22 1621 1629 10.1200/JCO.2004.08.065 1:CAS:528:DC%2BD2cXpsVWmu7k%3D 15117984 (Pubitemid 41079800)
3. M Ruiz J Salvador J Bayo, et al. 2008 Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer Cancer Chemother Pharmacol 62 1085 1090 10.1007/s00280-008-0709-7 1:CAS:528:DC%2BD1cXhtFaju77M 18365200
4. MD Pegram T Pienkowski DW Northfelt, et al. 2004 Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer J Natl Cancer Inst 96 759 769 1:CAS:528:DC%2BD2cXkt1Sqsbg%3D 15150304
5. EA Perez VJ Suman KM Rowland, et al. 2005 Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252 Clin Breast Cancer 6 425 432 10.3816/CBC.2005.n.047 1:CAS:528:DC%2BD28XosVOlsg%3D%3D 16381626
6. N Robert B Leyland-Jones L Asmar, et al. 2006 Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer J Clin Oncol 24 2786 2792 10.1200/JCO.2005.04.1764 1:CAS:528:DC%2BD28XntV2hu7g%3D 16782917 (Pubitemid 46630577)
7. JA Sparano M Wang S Martino, et al. 2008 Weekly paclitaxel in the adjuvant treatment of breast cancer N Engl J Med 358 1663 1671 10.1056/NEJMoa0707056 1:CAS:528:DC%2BD1cXkslCitLk%3D 18420499 (Pubitemid 351549913)
8. AD Seidman D Berry C Cirrincione, et al. 2008 Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840 J Clin Oncol 26 1642 1649 10.1200/JCO.2007.11. 6699 1:CAS:528:DC%2BD1cXltlWhsr0%3D 18375893
9. S Gori AM Mosconi C Basurtol, et al. 2002 Weekly paclitaxel in metastatic breast cancer patients: a phase II study Tumori 88 470 473 12597140
10. MC Green AU Buzdar T Smith, et al. 2005 Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks J Clin Oncol 23 5983 5992 10.1200/JCO.2005.06.232 1:CAS:528:DC%2BD2MXhtVKgtb3O 16087943 (Pubitemid 46300215)
11. EA Perez CL Vogel DH Irwin JJ Kirshner R Patel 2001 Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer J Clin Oncol 19 4216 4223 1:CAS:528:DC%2BD38XhslWqtA%3D%3D 11709565
12. JH Nettles H Li B Cornett JM Krahn JP Snyder KH Downing 2004 The binding mode of epothilone A on alpha, beta-tubulin by electron crystallography Science 305 866 869 10.1126/science.1099190 1:CAS:528:DC%2BD2cXmt1Krsbs%3D 15297674 (Pubitemid 39038421)
13. FY Lee R Borzilleri CR Fairchild, et al. 2001 BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy Clin Cancer Res 7 1429 1437 1:CAS:528: DC%2BD3MXktlels7Y%3D 11350914
14. EA Perez G Lerzo X Pivot, et al. 2007 Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine J Clin Oncol 25 3407 3414 10.1200/JCO.2006.09.3849 1:CAS:528:DC%2BD2sXhtVajsb%2FP 17606974 (Pubitemid 47310876)
15. E Thomas J Tabernero M Fornier, et al. 2007 Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer J Clin Oncol 25 3399 3406 10.1200/JCO.2006.08.9102 1:CAS:528:DC%2BD2sXhtVajsb%2FN 17606975 (Pubitemid 47310875)
16. JA Low SB Wedam JJ Lee, et al. 2005 Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer J Clin Oncol 23 2726 2734 10.1200/JCO.2005.10.024 1:CAS:528:DC%2BD2MXktleqtro%3D 15837987 (Pubitemid 46179462)
17. H Roche L Yelle F Cognetti, et al. 2007 Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy J Clin Oncol 25 3415 3420 10.1200/JCO.2006.09.7535 1:CAS:528:DC%2BD2sXhtVajsb%2FK 17606972 (Pubitemid 47310877)
18. N Denduluri JA Low JJ Lee, et al. 2007 Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes J Clin Oncol 25 3421 3427 10.1200/JCO.2006.10.0784 1:CAS:528:DC%2BD2sXhtVajsb%2FE 17606971 (Pubitemid 47310878)
19. A Awada MJ Piccart SF Jones, et al. 2009 Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy Cancer Chemother Pharmacol 63 417 425 10.1007/s00280-008-0751-5 1:CAS:528:DC%2BD1cXhsFejtrrE 18446338
20. R Plummer P Woll D Fyfe, et al. 2008 A phase I and pharmacokinetic study of ixabepilone in combination with carboplatin in patients with advanced solid malignancies Clin Cancer Res 14 8288 8294 10.1158/1078-0432.CCR-08-0471 1:CAS:528:DC%2BD1cXhsV2it7nN 19088046
21. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437
22. Kaplan EL, Meier P (1958) Nonparametric estimator from incomplete observations. J Am Stat Assoc 53:457-481
23. HS Rugo M Campone A Amadori, et al. 2009 Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC) J Clin Oncol 27 15s 10.1200/JCO.2008.21.7695 (suppl; abstr 1029)
24. JA Sparano 2000 Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials Clin Breast Cancer 1 32 40 10.3816/CBC.2000.n.002 1:STN:280:DC%2BD387mvVakug%3D%3D 11899388 discussion 1-2
25. E Rivera JA Mejia BK Arun, et al. 2008 Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer Cancer 112 1455 1461 10.1002/cncr.23321 1:CAS:528:DC%2BD1cXktlKrtbc%3D 18300256
26. Y Fromes P Gounon R Veitia MC Bissery A Fellous 1996 Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel J Protein Chem 15 377 388 10.1007/BF01886864 1:CAS:528: DyaK28Xkt1Gktrc%3D 8819014 (Pubitemid 26242162)
27. F Gueritte-Voegelein D Guenard F Lavelle MT Le Goff L Mangatal P Potier 1991 Relationships between the structure of taxol analogues and their antimitotic activity J Med Chem 34 992 998 10.1021/jm00107a017 1:CAS:528:DyaK3MXisVOmt7k%3D 1672159
28. J Verweij M Clavel B Chevalier 1994 Paclitaxel (Taxol) and docetaxel (Taxotere): not simply two of a kind Ann Oncol 5 495 505 1:STN:280: DyaK2M%2FgtFGrsw%3D%3D 7918121
29. Pegram MF, Forbes J, Pienkowski T et al (2007) BCIRG 007: first overall survival analysis of randomized phase III trial of trastuzumab plus docetaxel with or without carboplatin as first line therapy in HER2 amplified metastatic breast cancer (MBC). J Clin Oncol 2007; ASCO annual meeting proceedings, vol 25